Andrea Pérez González

It's been a pleasure to lead the organization of the hashtag#Evometconference2024 🔬 Thanks to all the participants for making it possible. It has been tremendously rewarding, after all the organizing efforts, enjoying 3 days full of science and enriching interactions. 💯

@CedricBlanpain @evomet_itn Thanks a lot Cédric. Hope to see you soon!

@Andreapg_1998 @evomet_itn Congratulations. Was so happy to have you in the lab. We will miss you a lot. Have fun with your postdoc !

Excited to share that on April 28th, I defended my PhD thesis🧬 Huge thanks to my supervisor @CedricBlanpain, my committee and jury, the @evomet_itn Marie Curie ITN, colleagues, family, and friends for their support throughout this journey. One chapter closes, another begins! 🚀

@AnqiDong18 @CedricBlanpain @evomet_itn Thank you ☺️

@Andreapg_1998 @CedricBlanpain @evomet_itn Congratulations!!!🥳

@JuanCarlosLpz13 Thanks a lot!!

@Andreapg_1998 Congratulations!! Very proud of you, my friend!! Hopefully we can celebrate your success soon!

This isn’t a random scientist who got lucky. Mariano Barbacid discovered the first human oncogene in 1982. He isolated H-RAS from bladder cancer cells and proved a single point mutation could trigger cancer. That finding launched the entire field of molecular oncology. KRAS mutations cause 90% of pancreatic cancers. For 43 years, oncologists called KRAS “undruggable” because the protein had no obvious binding pocket. Barbacid spent the last decade using genetically engineered mice to systematically test every node in the KRAS signaling pathway, looking for combinations that would work without killing the patient. The triple therapy blocks KRAS three ways at once: the main growth signal, the escape routes through EGFR and HER2, and the stress-response backup through STAT3. Cut the engine, seal the exits, disable the emergency system. Tumors vanished in mice and didn’t return for 200+ days after treatment stopped. Pancreatic cancer has a 13% five-year survival rate. 8% for the ductal adenocarcinoma type this therapy targets. Most patients live one year after diagnosis. The catch: this is preclinical. Human trials are 3+ years away. One of the drugs, RMC-6236, might get approved this year, but the full triple combination has regulatory hurdles. Still. The man who discovered human oncogenes in 1982 may have just figured out how to eliminate the cancer those genes cause. That’s a 43-year arc from first principles to potential cure. Science rarely works this clean.

This study reveals how an atypical EMT state with low stiffness—driven by actin depolymerization—can shield metastatic cells from immune cell-mediated killing during dormancy. A major step forward in understanding cancer metastasis and immune evasion! 🧬🔬

Excited to share that our News & Views on Wang et al.'s groundbreaking work is now published in @NatureCancer! 🎉 It was an honor to co-author this piece with @CedricBlanpain and highlight the latest research from @LabMassague. nature.com/articles/s4301…

I am delighted to share this new review in @NatureCancer that I co-author with @AnqiDong18 In which we discuss the different EMT tumor states and their implications for metastasis and cancer therapy.

NEW content online! Identification, functional insights and therapeutic targeting of EMT tumour states bit.ly/3IJ8haZ

I am delighted to share our new study uncovering the role of innate immunity in regulating cell plasticity and reprograming of prostate tumor initiating cells published in @NatureCancer . Congrats @ChenJiang919 and @yura__song , the first authors, nature.com/articles/s4301…

A gene-editing treatment used on a 9½-month-old boy with a rare condition has the potential to help people with thousands of other uncommon genetic diseases #NBTNewsBeat nytimes.com/2025/05/15/hea…

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by @US_FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe, rapidly progressing genetic disease... all in an astounding 7 months. Best of all, the infant patient shows apparent benefit. Congratulations to @kiranmusunuru, Rebecca Ahrens-Nicklas, and other team members for this heroic and inspiring effort, which has implications for the hundreds of millions of patients that suffer from thousands of genetic diseases. drive.google.com/file/d/1Jfku5j…

Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism" —the 1st human to undergo custom genome editing —outgrowth of decades of NIH funded research nejm.org/doi/full/10.10… nejm.org/doi/full/10.10… @NEJM nytimes.com/2025/05/15/hea…

So excited to finally share some of the main findings from my PhD, out today in @CellStemCell 🧵

Doing my PhD as part of the Evomet network has been a unique and enriching experience. 👇👇

@CedricBlanpain is one of the amazing supervisors of @adaptmet . Do not miss the opportunity to work with him and all the top-level scientists! We look forward to receiving your applications at adaptmet.eu/recruitment/

Adapmet is an amazing consortium working on cancer and metastasis and offers PhD positions. If you want to perform a PhD in these topics (either in academia or industry), please apply for these positions through the website interface before January 9th. Please forward the post!

¡Fin de semana inolvidable en Bruselas con más de 50 antiguos alumnos de UFV y ELU de Bélgica, Luxemburgo, Países Bajos y Francia! 🤝🎉 Establecimos nuestra Embajada UFVAlumni para crecer juntos, apoyarnos y llevar el espíritu UFV más allá de las fronteras. #UFVAlumni

👇 Interested in pursuing a PhD in metastasis research? Check this out. My lab @NKI_nl @oncodeinstitute is one of the host labs in this amazing @adaptmet consortium

📢 Calling all future cancer researchers! Adaptmet is offering 16 MSCA PhD positions in cutting-edge metastasis research. Join us to shape the future of cancer science with exciting projects among Europe’s best teams from top host institutions! Apply now 👉adaptmet.eu/recruitment/